At the news
? BULLISHIMPACT 8/10 6-K filed Apr 2, 2026 at 09:27 ET
AstraZeneca announced positive Phase III EMERALD-3 trial results showing that the combination of Imfinzi and Imjudo with lenvatinib and TACE significantly improved progression-free survival (PFS) in patients with embolisation-eligible unresectable liver cancer. The data, which also show a trend toward improved overall survival, support a potential new standard of care in earlier-stage hepatocellular carcinoma (HCC) and are being shared with regulators.
- EMERALD-3 Phase III trial met primary endpoint: statistically significant and clinically meaningful improvement in PFS for Imfinzi + Imjudo + lenvatinib + TACE vs TACE alone in unresectable HCC.
- Interim analysis shows trend toward improved overall survival (OS), a key secondary endpoint.
- Trial included 760 patients across 171 centers in 22 countries.
- STRIDE regimen (durvalumab + tremelimumab) forms the immunotherapy backbone; builds on prior HIMALAYA trial success in advanced HCC.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access